Zolmitriptan Propranolol

Similarly, in healthy volunteers co-administration of propranolol resulted in a 56% increase in the AUC of zolmitriptan and a 11% decrease in the AUC of its active metabolite (28). 

Clinically important, potentially hazardous interactions with acenocoumarol, alfuzosin, aminophylline, anisindione, anticoagulants, buprenorphine, butorphanol, caffeine, carmustine, dobazam, cocoa, dicumarol, dofetilide, duloxetine, epirubicin, eszopiclone, fentanyl, floxuridine, fluorouracil, galantamine, gliclazide, hydromorphone, itraconazole, ketoconazole, lidocaine, meptazinol, midazolam, mizolastine, modobemide, morphine, narcotic analgesics, oxprenolol, oxycodone, pentazocine, phenytoin, posaconazole, prednisone, propranolol, sufentanil, tolazoline, warfarin, xanthines, zaleplon, zofenopril, zolmitriptan, zolpidem... 

Metoprolol Midazolam Naproxen Nifedipine Omeprazole Ondansetron Orphenadrine Phenytoin Piroxicam Progesterone Propafenone Propranolol Quinidine Rifampin Sibutramine Sildenafil Simvastatin Tacrine Tamoxifen Terfenadine Testosterone Theophylline Timolol Tolbutamide Tramadol Triazolam Verapamil Warfarin (R) Warfarin (S) Zolmitriptan Zolpidem... 

In a double-blind, randomised, crossover study, 12 healthy subjects were given propranolol 160 mg or a placebo daily for 7 days, with a single 10-mg oral dose of zolmitriptan on day 7. The propranolol increased the maximum serum levels and the AUC of the zolmitriptan by 56% and 37%, respectively, and reduced the extent of its conversion to its active metabolite, probably due to inhibition of, or competition for metabolism by, cytochrome P450 isoenzymes. However, it was concluded that no clinically important changes in the therapeutic effects of zolmitriptan are likely, nor are any adjustments in its dosage needed. ... 

Peck RW, Seaber EJ, Dixon R, Gillotin CG, Weatherley BC, Layton G, Posner J. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). BrJ Clin Pharmacol (1997) 44, 595-9. 

---